1. Use of
patisiran, an
RNA interference therapy, in patients with hereditary
transthyretin (hATTR) cardiac amyloidosis was linked to reduced left ventricular global longitudinal strain (LVGLS) compared with placebo. 2. The therapy-associated reduction in ventricular myocardial strain was greatest for the basal region. The mid and apical regions of the LV did not have significant […]